In a report released yesterday, Jason Gerberry from Bank of America Securities reiterated a Buy rating on Oculis Holding, with a price target of $28.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jason Gerberry has given his Buy rating due to a combination of factors including Oculis Holding’s robust financial position and promising clinical pipeline. The company has successfully extended its cash runway into early 2028, ensuring financial stability as it progresses through key clinical trials. Notably, Oculis is advancing its lead asset, OCS-01, with phase 3 trials for diabetic macular edema on track for a significant data readout in the first half of 2026.
Furthermore, the strategic focus on privosegtor, a neuroprotective candidate, is seen as a long-term value driver with potential applications in multiple indications. The planned initiation of phase 2b trials for privosegtor in NAION and multiple sclerosis relapses adds to the company’s growth prospects. Gerberry views the underappreciated pipeline assets and the company’s strategic execution as compelling reasons for the Buy rating and a price objective of $28.